These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 33682714

  • 1. Elevated Inflammatory Markers and Arterial Stiffening Exacerbate Tau but Not Amyloid Pathology in Older Adults with Mild Cognitive Impairment.
    Clark AL, Weigand AJ, Thomas KR, Solders SK, Delano-Wood L, Bondi MW, Bernier RA, Sundermann EE, Banks SJ, Bangen KJ, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2021; 80(4):1451-1463. PubMed ID: 33682714
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 3. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
    He B, Wang L, Xu B, Zhang Y, Alzheimer’s Disease Neuroimaging Initiative.
    Neurosci Lett; 2021 May 29; 754():135765. PubMed ID: 33667602
    [Abstract] [Full Text] [Related]

  • 4. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J.
    Exp Gerontol; 2017 Dec 15; 100():45-53. PubMed ID: 29054536
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status.
    Rehman H, Ang TFA, Tao Q, Espenilla AL, Au R, Farrer LA, Zhang X, Qiu WQ, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2024 Dec 15; 97(2):621-633. PubMed ID: 38143358
    [Abstract] [Full Text] [Related]

  • 6. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE, Norton D, Anderson ED, Wahoske M, Washington DT, Umucu E, Koscik RL, Dowling NM, Johnson SC, Carlsson CM, Asthana S, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2018 Dec 15; 61(1):79-89. PubMed ID: 29125485
    [Abstract] [Full Text] [Related]

  • 7. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.
    J Alzheimers Dis; 2016 Jul 29; 54(1):157-68. PubMed ID: 27472875
    [Abstract] [Full Text] [Related]

  • 8. Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment.
    Ahmad S, Yang W, Orellana A, Frölich L, de Rojas I, Cano A, Boada M, Hernández I, Hausner L, Harms AC, Bakker MHM, Cabrera-Socorro A, Amin N, Ramírez A, Ruiz A, Van Duijn CM, Hankemeier T.
    Alzheimers Res Ther; 2024 Jul 30; 16(1):171. PubMed ID: 39080778
    [Abstract] [Full Text] [Related]

  • 9. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
    Drake JD, Chambers AB, Ott BR, Daiello LA, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2021 Jul 30; 80(4):1553-1565. PubMed ID: 33720880
    [Abstract] [Full Text] [Related]

  • 10. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J, Oikonomidi A, Tautvydaitė D, Dayon L, Bacher M, Migliavacca E, Henry H, Kirkland R, Severin I, Wojcik J, Bowman GL.
    Brain Behav Immun; 2017 May 30; 62():203-211. PubMed ID: 28161476
    [Abstract] [Full Text] [Related]

  • 11. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M.
    Alzheimers Res Ther; 2019 Dec 05; 11(1):99. PubMed ID: 31805990
    [Abstract] [Full Text] [Related]

  • 12. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Li QX, Ames D, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM, AIBL Research Group.
    J Alzheimers Dis; 2018 Dec 05; 66(3):1193-1211. PubMed ID: 30412495
    [Abstract] [Full Text] [Related]

  • 13. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J, Verhülsdonk S, Pessanha F, Menge T, Seitz RJ, Kujovic M, Höft B, Supprian T, Lange-Asschenfeldt C.
    J Alzheimers Dis; 2019 Dec 05; 72(4):1119-1127. PubMed ID: 31683478
    [Abstract] [Full Text] [Related]

  • 14. Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults.
    Kresge HA, Liu D, Gupta DK, Moore EE, Osborn KE, Acosta LMY, Bell SP, Pechman KR, Gifford KA, Mendes LA, Wang TJ, Blennow K, Zetterberg H, Hohman TJ, Jefferson AL.
    J Alzheimers Dis; 2020 Dec 05; 74(3):965-974. PubMed ID: 32144980
    [Abstract] [Full Text] [Related]

  • 15. Performance of Validated MicroRNA Biomarkers for Alzheimer's Disease in Mild Cognitive Impairment.
    Sandau US, Wiedrick JT, Smith SJ, McFarland TJ, Lusardi TA, Lind B, Harrington CA, Lapidus JA, Galasko DR, Quinn JF, Saugstad JA.
    J Alzheimers Dis; 2020 Dec 05; 78(1):245-263. PubMed ID: 32955460
    [Abstract] [Full Text] [Related]

  • 16. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.
    Bipolar Disord; 2016 Feb 05; 18(1):63-70. PubMed ID: 26876913
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 05; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 18. Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study.
    Pais M, Loureiro J, do Vale V, Radanovic M, Talib L, Stella F, Forlenza O.
    J Alzheimers Dis; 2021 Jan 05; 81(3):949-962. PubMed ID: 33843685
    [Abstract] [Full Text] [Related]

  • 19. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S, Santangelo R, Bernasconi MP, Cecchetti G, Fiorino A, Pinto P, Passerini G, Falautano M, Comi G, Magnani G.
    J Alzheimers Dis; 2016 Oct 18; 54(4):1495-1508. PubMed ID: 27589522
    [Abstract] [Full Text] [Related]

  • 20. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A.
    J Alzheimers Dis; 2015 Oct 18; 45(4):1077-88. PubMed ID: 25649653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.